Related Experiment Video
Updated: Dec 2, 2025
08:48
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
3.2K
The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
Daniele Focosi1, Albert Farrugia2
1North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
Abstract:
COVID-19 convalescent plasma (CCP) is widely used as a treatment. While safety data are enough, high-level evidences of efficacy are still missing. We summarize here the results from randomized controlled trials (RCT) published to date and analyze their flaws and biases. We then provide suggestions for next round of CCP RCTs, discussing specification of CCP, therapeutic dose, timing, control arm, disease stage, and outcome measures.
